Next Article in Journal
Comparison of Synthetic Methods and Identification of Several Artificial Antigens of Deoxynivalenol
Next Article in Special Issue
Visible Light-Induced Cascade Sulfonylation/Cyclization to Produce Quinoline-2,4-Diones under Metal-Free Conditions
Previous Article in Journal
Artemisia vestita: A Folk Medicine with Hidden Herbal Fortune
Previous Article in Special Issue
Synthesis and Application Dichalcogenides as Radical Reagents with Photochemical Technology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 6
10.3390/molecules28062787
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

One-Pot Synthesis of Isoxazole-Fused Tricyclic Quinazoline Alkaloid Derivatives via Intramolecular Cycloaddition of Propargyl-Substituted Methyl Azaarenes under Metal-Free Conditions

by
Zhuo Wang
1,
Yuhan Zhao
1,
Jiaxin Chen
1,
Mengyao Chen
1,
Xuehan Li
1,
Ting Jiang
1,
Fang Liu
1,
Xi Yang
1,
Yuanyuan Sun
1 and
Yanping Zhu
1,2,*
1
Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai 264005, China
2
Anhui Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu 241000, China
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(6), 2787; https://doi.org/10.3390/molecules28062787
Submission received: 14 February 2023 / Revised: 14 March 2023 / Accepted: 15 March 2023 / Published: 20 March 2023
(This article belongs to the Special Issue Synthesis and Modification of Nitrogen Heterocyclic Compounds)
Browse Figures
Versions Notes

Abstract

:
A practical method was developed for the convenient synthesis of isoxazole-fused tricyclic quinazoline alkaloids. This procedure accesses diverse isoxazole-fused tricyclic quinazoline alkaloids and their derivatives via intramolecular cycloaddition of methyl azaarenes with tert-butyl nitrite (TBN). In this method, TBN acts as the radical initiator and the source of N–O. Moreover, this protocol forms new C–N, C–C, and C–O bonds via sequence nitration and annulation in a one-pot process with broad substrate scope and functionalization of natural products.

1. Introduction

Quinazolinones are a well-known family of N-heterocyclic compounds with bioactivities [1,2,3,4,5,6] on multiple fronts and occur often in natural products [7,8,9,10]. Recently, a group of special tricyclic quinazoline alkaloids, such as 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-ones, have attracted increased attention from medicinal chemists and biologists for their bioactivity levels in areas such as antitumor, antibacterial, anti-inflammatory and anti-acetylcholinesterase activities [11,12,13,14,15,16]. Key examples include deoxyvasicinone and vasicinone isolated from the adhatoda vasica medicinal plant, with pronounced anti-inflammatory, antimicrobial, and antidepressant activities (Figure 1) [17,18,19,20]. Luotonin A and evodiamine are promising anticancer natural products that act as topoisomerase I inhibitors [21,22]. Anisulcusine B, isolated from anisotes trisulcus, showed moderate cytotoxic effect against human hepatoma (HuH7) cells [23]. Rutaecarpine is an inhibitor of COX-2 with an IC50 value of 0.28 μM [24].
The ubiquitous nature and importance in pharmaceutical research have led to several reported synthetic methodologies for 2,3-fused quinazoline-4(3H)-ones and their derivatives (Scheme 1a) [25,26,27,28]: (1) N-Cyanamide alkenes react with aldehydes or diketones via intramolecular cyclization difunctionalization [18], [29,30,31]; (2) intramolecular radical cyclization of N3-Alkenyl-tethered quinazolinone [32,33,34,35]; (3) oxidative cyclization of isatins or isatoic anhydrides with cyclic amines by ring opening strategy [36,37]; (4) cyclic amines undergo a dehydrogenation process including intermolecular and intramolecular cyclization [38,39,40,41]; (5) 2-Arylquinazolinones undertake a cyclization reaction via transition metal catalysis [42,43].
Isoxazole is a five-membered heterocycle with two adjacent heteroatoms and a cyclic conjugated system, which could react with target proteins via multiple noncovalent bonds [44,45,46]. This feature of isoxazole makes it a key pharmaceutical fragment in many drugs [47,48,49]. In recent years, tert-butyl nitrite (TBN) has acted as a metal-free radical initiator and source of N-O [50,51,52,53,54,55,56,57,58,59], which has attracted extensive attention in the construction of isoxazoles [60,61,62,63,64,65,66,67,68,69]. Despite these excellent methods, there are few reports on the construction of skeletal cores containing isoxazole and tricyclic quinazoline alkaloids or their derivatives. Recent literature reports have focused primarily on the formation of isoxazole-substituted methyl azaarenes from intermolecular reactions via tert-butyl nitrite. For example, Zhang and co-workers reported a graceful method for the synthesis of 3-quinolinyl-isoxazoles from 2-methyl quinolines, ethyl propiolate, and TBN under metal-free conditions [70]. Yang et al. developed copper-catalyzed 1,3-dipolar cycloaddition of alkylazaarenes with alkynes to synthesize isoxazoles, in which the nitro sources were generated in situ from KNO3 and K2S2O8 [71,72]. Song et al. developed an elegant protocol to synthesize isoxazoles via divergent annulation of sulfoxonium ylides with t-BuONO [73]. To the best of our knowledge, the formation of isoxazole fusing 2,3-dihydropyrrolo[2,1-b]quinazoliones or other tricyclic quinazoline alkaloids remains challenging and difficult, with no synthetic procedures previously reported.
Recently, our group had successfully demonstrated an efficient synthetic method to synthesize furoxans from methyl azaarene and t-BuONO [74]. Inspired by these brilliant works, herein we disclose an efficient and practical method for the synthesis of isoxazole-fused quinazolinones or quinolines from 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-ones and 2-methyl-3-(prop-2-yn-1-yloxy)quinolines with TBN via metal-free conditions in a single reaction (Scheme 1c).

2. Results and Discussion

2.1. Reaction Optimization

We selected 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (1a) as the model substrate to optimize the reaction conditions and to verify the feasibility of our assumption (Table 1). We initially treated 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one and TBN in DMSO at 80 °C for 6 h, which yielded the desired 4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2a) in a 45% yield (Table 1, entry 1). We varied the solvent (DMF, 1,4-dioxane, and acetonitrile; Table 1, entries 2–4). Acetonitrile afforded the desired product in a 64% yield. Temperature modification (Table 1, entries 4–6) confirmed 100 °C as the optimal reaction temperature. Adding TBN (4.5, 5, 5.5, and 6 eq.) was examined, which resulted in yields of 61%, 65%, 72%, and 70%, respectively, indicating that 5.5 eq. of TBN optimized the yield. Conducting the reaction under argon increased the yield of 2a to 75% (Table 1, entry 8). Adding 0.5 eq. of NCS (N-chlorosuccinimide) increased the yield to 76% (entry 9). We also screened several acids to determine their influence on the annulation reaction. Using trifluoroacetic acid (TFA) decreased the yield of the desired product 2a to 46% (entry 10); however, adding acetic acid increased the yield increased to 80% (entry 11). Aliphatic and aromatic carbonic acids did not promote this reaction effectively (entries 12–17).

2.2. Substrate Scope

After the optimum conditions were established, the substrate scope of 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one for the formation of 4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one 2 was evaluated. As shown in Figure 2, a series of electron-donating groups on the phenyl ring of 1, such as the methyl groups at the C-4, C-4,6, C-5,6 position (1b–1d) and the methoxyl group at the C-5 position (1e), could participate in this reaction to afford the corresponding products in 73–83% yields (2b–2e). To our delight, 1 with a phenyl group in the position of C-5 (1g–1h) gave the corresponding products smoothly in 75% and 50% yields, respectively. However, 1f was not tolerated in the reaction under the optimized conditions, giving the desired product in a very low yield. Meanwhile, electron-drawing groups on the phenyl ring of 1 proceeded well via our protocol, such as the fluoro group at the position C-5, C-4,5 (1i–1j), the chloro and nitro group at the C-4 position (1k–1l), leading to the desired products in good yields (60–76%). To our delight, heteroatom-contained substrate 1m was also suitable for this reaction to afford the desired product 2m in 46% yield. In addition, the substrates of the substituted alkynyl group were also tested; those results showed that alkynyl substituted substrate (1n) was unsuitable for this reaction.
To further investigate the universality of our method, a variety of substituted 2-methyl-3-(prop-2-yn-1-yloxy)quinolines were surveyed. As shown in Figure 3, 2-methyl-3-(prop-2-yn-1-yloxy)quinoline (3a) was smoothly transformed into the corresponding product with a yield of 80%. Substrates of substituted groups on the phenyl ring 3b and 3c were applied to this reaction, which yielded products 4b and 4c in 77% and 24% yields, respectively. Then, ester-substituted substrates in the C-4 position were also screened, and all substrates were transformed smoothly to obtain the desired products in moderate to good yields (4d–4h, 56–79%). Moreover, different amide-substituted substrates on the C-4 position (3i–3j) were tested, processing the corresponding products 4i and 4j in 43% and 51% yields, respectively.
Furthermore, to evaluate the application of the present reaction. Several natural products were modified via our protocol. As shown in Figure 4, 2-methyl-3-(prop-2-yn-1-yloxy)quinoline-4-carboxylic acid reacted with natural alcohols to generate ester derivates 3. The L-menthol and sugar methyl 2,3-O-isopropylideneisopropylidene-β-D-ribofuranoside could be involved in this protocol, giving the desired products (4k–4l) in 22–35% yields. The 3m phytol derivate was smoothly transformed into the corresponding product with a yield of 67%. Two natural steroids, cholesterol and stigmasterol, were also screened, affording the corresponding products (4n–4o) in 29–33% yields.

2.3. Mechanism Experiments

Several control experiments were carried out to explore the reaction mechanism (Scheme 2). The reaction was halted completely with only trace amounts of 2a, when 3.5 equivalent of radical scavenger 2,2,6,6-tetramethyl-1-piperidinyl (TEMPO) was added to the standard reaction. These results indicated that the reaction was conducted possibly through a radical pathway. Then, 2-methyl-3-(prop-2-yn-1-yl)quinazolinone (1a) and TBN were reacted under standard conditions for 20 min to address the possible intermediates. Only 2a 4H,6H-isoxazolo-pyrrolo[2,1-b]quinazolin-6-one was detected by MS (APCI), because the intermediate nitrile oxide F (Scheme 3) shares the same relative molecular mass as 2a. Then, we tried other ways to prove them by conducting substrates 5a 2-methyl-3-phenyl quinazoline-4(3H)-one under standard conditions for 20 min to detect 5ac nitrile oxides via MS (APCI) (see Supplementary Materials). A group of intermolecular reactions was used to explore the reaction mechanism further by using 5a, 5ab, and phenylacetylene. Under optimal conditions, the desired product 6a was afforded in yields of 56% and 65%, respectively. These results disclosed that nitrile oxide was the potential intermediate for this protocol.
Based on the evidence presented above and the related literature [75,76,77], a plausible reaction pathway was proposed (Scheme 3). Firstly, TBN was transformed to NO and t-BuO radicals via thermal homolysis. 2-Methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (1a) could be transformed into intermediate isomer A via acid promotion, which reacts with TBN to produce intermediate B and releases a tert-butoxy radical. Then, intermediate C from oxidation of intermediate B undergoes tautomerization to generate oxime D, which can be further converted into intermediate E via NCS. Subsequently, the intermediate E can be oxidized to afford the nitrile oxides F, which could be transformed into the desired product 2a through 1,3-dipolar cycloaddition.

3. Materials and Methods

3.1. General Information

Analytical thin layer chromatography (TLC) was performed using pre-coated silica gel HF254 glass plates. Column chromatography was performed using silica gel (200–300 mesh). Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Advance 500 MHz spectrometer at ambient temperature using DMSO-d6 or CDCl3 as the solvent with tetramethylsilane (TMS) as the internal standard at room temperature (1H δ 7.26 ppm and 13C{1H} δ 77.0 ppm for CDCl3; 1H δ 2.50 ppm and 13C{1H} δ 39.5 ppm for DMSO-d6). Chemical shifts (δ) are reported in ppm, relative to the internal standard of tetramethylsilane (TMS). The coupling constants (J) are quoted in hertz (Hz). Resonances are described as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad) or combinations thereof. High-resolution mass spectra were obtained on Thermo Scientific Q-Exactive (ESI mode). Melting points were determined using SGW X-4 apparatus and were not corrected.

3.2. Synthetic Procedures

Compounds 1a–1l were prepared according to the referenced literature (Scheme 4) [78]. To corresponding 2-aminobenzoic acid (1 mmol) was added acetic anhydride (5 mmol), and the mixture was warmed to 120 °C for 3 h with stirring. The mixture was then concentrated in vacuo (50 °C) to remove excess acetic anhydride (bp 138 °C) to give a dry solid. Ammonium hydroxide (28% NH3, 100 mL) was added, and the mixture was heated to 95 °C for 4 h. The mixture was cooled, vacuum filtered and the resultant solid washed with water, saturated with NaHCO3 solution and more water. The 3-bromopropyne (1.5 equiv.) was dropped into the solution of the obtained solid, t-BuOK (1.3 equiv.) and DMF under Argon atmosphere at 0 °C to r.t overnight. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the corresponding products [79].
Compound 1m was prepared according to the referenced literature with some modification (Scheme 5) [80]. A Schlenk flask was charged with a magnetic stirrer, evacuated and backfilled with argon. 2-Chloronicotinic acid (0.5 mmol) and acetamidine hydrochloride (0.75 mmol) in EtOH (3 mL) were added under Argon atmosphere. After 10 min of stirring, Cs2CO3 (1 mmol) was added to the flask. Then, 15 min later, CuI (0.1 mmol) was added to the flask. The mixture was stirred at 80 °C for 12 h. After completion of the reaction, the mixture was filtered, and the solvent of the filtrate was removed with the aid of a rotary evaporator. The residue was purified by column chromatography on silica gel to provide the desired quinazolinone. The 3-Bromopropyne (1.5 equiv.) was dropped into the solution of the obtained solid, t-BuOK (1.3 equiv.), and DMF under argon atmosphere at 0 °C to overnight. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the desired products.
7-Chloro-2-methylquinazolin-4(3H)-one was prepared from the above procedure. A Schlenk flask was charged with a 7-chloro-2-methylquinazolin-4(3H)-one (0.3 mmol), corresponding to phenylboronic acid (0.45 mmol), Pd(OAc)2 (0.05 mmol), Sphos (0.03 mmol) and K3PO4 (2.4 mmol), and was heated in toluene (2 mL) at 80 °C for 24 h. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the corresponding products [81]. The 3-bromopropyne (1.5 equiv.) was dropped into the solution of the obtained solid, t-BuOK (1.3 equiv.), and DMF under argon atmosphere at 0 °C to r.t overnight. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the desired products (Scheme 6).

3.2.1. Typical Procedure (TP 1) for the Synthesis of 2 and 4 Taking 2a as an Example

A sealed tube charged with 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one (1a) (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol) and AcOH (0.1mmol) were heated in acetonitrile (2 mL) at 100 °C for 10 h under argon atmosphere. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the corresponding products 2a.
Compound 4a–4c were prepared according to the referenced literature (Scheme 7) [82]. A solution of MeONa (1.5 mmol) in MeOH was added to a stirred solution of the corresponding 2-nitrobenzaldehyde (1.5 mmol) and a chloracetone (1.5 mmol) in MeOH (3.5 mL) at room temperature overnight. After the reaction was completed, the resulting precipitate was filtered off, the mixture was quenched carefully with water (3 × 50 mL) and with saturated NH4Cl (1 × 10 mL), and the product was isolated as a corresponding (2-(2-nitrophenyl)oxiran-1-yl)(aryl)methanone. A solution of Na2S2 O4 (5 mmol) in H2O (65 mL) was added to a solution of (2-(2-nitrophenyl)oxiran-1-yl)(aryl)methanone (1 mmol) in dioxane (65 mL). The reaction mixture was allowed to cool down to room temperature after reflux for 3 h and was poured into water (500 mL). The resulting precipitate was filtered off, washed with water (2 × 50 mL) and dried in air to give the corresponding 2-arylquinolin-3-ols. The 3-bromopropyne (3 equiv.) was dropped into the solution of the obtained solid, K2CO3 (3 equiv.), and acetonitrile under argon atmosphere at 0 °C to r.t overnight. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the desired products [83,84].
To a solution of 3-hydroxy-2-methyl-4-quinolinecarboxylic acid (1.1 equiv.), ROH or secondary amine (1.0 equiv.), DCC (1.1 equiv.) and DMAP (0.1 equiv.) were added in CH2Cl2 overnight to obtain 3-hydroxy-2-methylquinoline-4-carboxylate [85]. The 3-bromopropyne (3 equiv.) was dropped into the solution of the obtained solid, K2CO3 (3 equiv.), and acetonitrile under argon atmosphere at 0 °C to r.t overnight. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the desired products (Scheme 8).
Compound 5ab was prepared according to the referenced literature (Scheme 9) [86,87,88]. A mixture of isatoic anhydride (2 mmol), aniline (2 mmol) and triethyl orthoacetate (2 mmol) was reacted under 120 °C for 4 h. After completion of the reaction, the crude reaction mixture was recrystallized from EtOH to obtain analytically pure product 5a. Then, 5a (0.5 mmol) and SeO2 (6.5 mmol) were stirred at 80 °C in 1,4-dioxane for 3 h to corresponding aldehyde. A solution of the corresponding aldehyde (0.5 mmol) in pyridine (6 mL) was added to the solution of hydroxylamine hydrochloride (0.5 mmol), keeping the reaction mixture overnight. Then, the mixture was filtered and washed water to obtain the 5ab.

3.2.2. Typical Procedure (TP 2) for the Synthesis of 6a

A sealed tube charged with 2-methyl-3-phenyl quinazoline-4(3H)-one (5a) or (E)-4-oxo-3-phenyl-3,4-dihydroquinazoline-2-carbaldehyde oxime (5ab) (0.2 mmol), phenylacetylene (0.22 mmol), TBN (1.1 mmol), NCS (0.1 mmol) and AcOH (0.1mmol) was heated in acetonitrile (2 mL) at 100 °C for 10 h under argon atmosphere. After the reaction was completed, 50 mL water was added to the mixture and then extracted with EtOAc 3 times (3 × 50 mL). The extract was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude residues were purified by column chromatography using ethyl acetate/petroleum ether mixture to obtain the corresponding products 6a.

3.3. Characterization of Products

4H,6H-Isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2a), 40 mg, brown solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.26 (dd, J = 8.0, 1.5 Hz, 1H), 7.93 (td, J = 7.6, 7.0, 1.5 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.69–7.62 (m, 1H), 5.03 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.4, 159.7, 154.7, 150.0, 145.3, 134.7, 127.9, 126.0, 120.8, 119.7, 43.3. HRMS (ESI): m/z [M+H]+ calcd for C12H7N3O2: 226.0611; found: 226.0610.
8-Methyl-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2b), 38 mg, white solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.06 (s, 1H), 7.76 (q, J = 8.4 Hz, 2H), 5.02 (s, 2H), 2.50 (s, 9H). 13C NMR (126 MHz, DMSO-d6) δ 163.3, 159.6, 154.6, 146.0, 144.5, 137.9, 135.9, 127.8, 125.3, 120.6, 119.6, 43.2, 20.9. HRMS (ESI): m/z [M+H]+ calcd for C13H9N3O2: 240.0768; found: 240.0763.
9,10-Dimethyl-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2c), 38 mg, white solid, m.p.: 259–260 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 8.1 Hz, 1H), 4.99 (s, 2H), 2.55 (s, 3H), 2.43 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 163.5, 159.9, 154.6, 146.2, 144.1, 143.4, 134.2, 129.5, 122.8, 119.6, 118.7, 43.0, 20.5, 13.1. HRMS (ESI): m/z [M+H]+ calcd for C14H11N3O2: 254.0924; found: 254.0924.
8,10-Dimethyl-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2d), 42 mg, white solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.20 (s, 1H), 7.91 (s, 1H), 7.63 (s, 1H), 5.03 (s, 2H), 2.60 (s, 3H), 2.46 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 163.4, 159.8, 154.5, 144.5, 143.6, 137.3, 136.5, 135.9, 123.1, 120.7, 119.6, 43.2, 20.9, 17.3. HRMS (ESI): m/z [M+H]+ calcd for C14H11N3O2: 254.0924; found: 254.0924.
9-Methoxy-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2e), 37 mg, white solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.21 (s, 1H), 8.15 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 2.5 Hz, 1H), 7.22 (dd, J = 8.9, 2.5 Hz, 1H), 5.01 (s, 2H), 3.94 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 164.2, 163.4, 159.3, 154.7, 150.3, 145.8, 127.5, 119.8, 117.2, 114.3, 109.2, 55.9, 43.2. HRMS (ESI): m/z [M+H]+ calcd for C13H9N3O3: 256.0717; found:256.0714.
9-(p-Tolyl)-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2g), 47 mg, white solid, m.p.: 271–272 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.29 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 8.4, 1.9 Hz, 1H), 7.77 (d, J = 7.8 Hz, 2H), 7.35 (d, J = 7.8 Hz, 2H), 5.04 (s, 2H), 2.38 (s, 3H). 13C NMR (126 MHz, DMSO-d6) δ 163.4, 159.6, 154.7, 148.6, 146.0, 145.6, 138.4, 135.4, 129.8, 127.1, 126.6, 126.2, 124.9, 119.8, 119.4, 43.3, 20.7. HRMS (ESI): m/z [M+H]+ calcd for C19H13N3O2: 316.1081; found:316.1081.
9-(4-Methoxyphenyl)-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2h), 33 mg, yellow solid, m.p.: 252–253 °C. 1H NMR (500 MHz, DMSO-d6) 9.22 (d, J = 1.2 Hz, 1H), 8.27 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.94 (dd, J = 8.3, 1.9 Hz, 1H), 7.87–7.81 (m, 2H), 7.12–7.07 (m, 2H), 5.06–5.03 (m, 2H), 3.83. 13C NMR (126 MHz, DMSO-d6) δ 163.4, 160.0, 159.6, 154.7, 148.6, 145.7, 145.6, 130.5, 128.5, 126.6, 125.9, 124.4, 119.8, 119.1, 114.7, 55.3, 43.3. HRMS (ESI): m/z [M+H]+ calcd for C19H13N3O3: 332.1030; found:332.1030.
9-Fluoro-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2i), 36 mg, white solid, m.p.:277–278 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.23 (d, J = 1.3 Hz, 1H), 8.30 (dd, J = 8.9, 6.2 Hz, 1H), 7.69 (dd, J = 10.0, 2.6 Hz, 1H), 7.51 (td, J = 8.7, 2.6 Hz, 1H), 5.02 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ165.7 (d, J = 251.5 Hz), 163.2, 159.1, 154.9, 150.3 (d, J = 13.4 Hz), 146.7, 129.0 (d, J = 11.0 Hz), 119.9, 117.9(d, J = 2.52 Hz), 116.4 (d, J = 23.3 Hz), 113.1 (d, J = 22.1 Hz), 43.5. HRMS (ESI): m/z [M+H]+ calcd for C12H6FN3O2: 244.0517; found: 244.0512.
8,9-Difluoro-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2j), 39 mg, white solid, m.p.:224–226 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.24 (s, 1H), 8.19 (td, J = 9.3, 3.3 Hz, 1H), 8.02 (td, J = 8.7, 7.5, 3.0 Hz, 1H), 5.03 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.2, 158.5, 155.0, 153.9 (dd, J = 251.5, 14.5 Hz), 149.2 (dd, J = 251.5, 16.1 Hz), 146.3, 146.0 (dd, J = 11.1, 2.6 Hz), 119.8, 118.4 (d, J = 7.2 Hz), 116.1 (d, J = 17.9 Hz), 113.7 (d, J = 18.8 Hz), 43.6. HRMS (ESI): m/z [M+H]+ calcd for C12H5F2N3O2: 262.0423; found: 262.0422.
8-Chloro-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2k), 39 mg, white solid, m.p.:248–250 °C, 1H NMR (500 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.16 (d, J = 2.5 Hz, 1H), 7.94 (dd, J = 8.7, 2.5 Hz, 1H), 7.89 (d, J = 8.7 Hz, 1H), 5.02 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.2, 158.7, 154.9, 146.7, 145.7, 134.8, 132.2, 130.1, 124.9, 122.1, 119.7, 43.5. HRMS (ESI): m/z [M+H]+ calcd for C12H6ClN3O2: 260.0221; found: 260.0220.
8-Nitro-4H,6H-isoxazolo[3′,4′:3,4]pyrrolo[2,1-b]quinazolin-6-one (2l), 32 mg, yellow solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.28 (s, 1H), 8.90 (d, J = 2.7 Hz, 1H), 8.64 (dd, J = 8.9, 2.7 Hz, 1H), 8.08 (d, J = 8.9 Hz, 1H), 5.08 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.1, 159.0, 155.3, 152.2, 148.4, 145.7, 129.7, 128.7, 121.9, 121.1, 120.0, 43.9. HRMS (ESI): m/z [M+H]+ calcd for C12H6N4O4: 271.0462; found: 271.0641.
4H,6H-Isoxazolo[3′,4′:3,4]pyrrolo[1,2-a]pyrido[2,3-d]pyrimidin-6-one (2m), 21mg, white solid, m.p.: over 280 °C. 1H NMR (500 MHz, DMSO-d6) δ 9.27 (d, J = 1.6 Hz, 1H), 9.07 (dd, J = 4.5, 2.0 Hz, 1H), 8.66 (dd, J = 7.9, 2.1 Hz, 1H), 7.68 (dd, J = 7.9, 4.6 Hz, 1H), 5.05 (s, 2H). 13C NMR (126 MHz, DMSO-d6) δ 163.3, 160.2, 158.1, 156.1, 155.0, 148.3, 135.7, 123.2, 119.8, 116.3, 43.6. HRMS (ESI): m/z [M+H]+ calcd for C11H6N4O2: 227.0564; found:227.0560.
4H-Isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline (4a), 36 mg, brown solid, m.p.: 194–196 °C. 1H NMR (500 MHz, CDCl3) δ 8.40 (s, 1H), 8.21 (d, J = 8.5 Hz, 1H), 7.74–7.68 (m, 2H), 7.62 (dd, J = 8.5, 6.7 Hz, 1H), 7.53 (t, J = 7.5 Hz, 1H), 5.35 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 154.1, 152.0, 148.9, 144.6, 137.0, 130.2, 130.0, 128.2, 128.1, 126.7, 120.9, 113.8, 61.5. HRMS (ESI): m/z [M+H]+ calcd for C13H8N2O2: 225.0659; found: 225.0658.
8-Chloro-4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline (4b), 39 mg, White solid, m.p.: 273–274 °C. 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.15 (d, J = 9.0 Hz, 1H), 7.72 (d, J = 2.5 Hz, 1H), 7.62 (s, 1H), 7.55 (dd, J = 9.1, 2.3 Hz, 1H), 5.38 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 153.8, 152.2, 149.5, 142.9, 137.2, 134.1, 131.6, 130.8, 129.3, 125.3, 120.0, 113.6, 61.7. HRMS (ESI): m/z [M+H]+ calcd for C13H7ClN2O2: 259.0269; found: 259.0269.
4H-[1,3]Dioxolo[4,5-g]isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline (4c), 13 mg, brown solid, m.p.: over 280 °C. 1H NMR (500 MHz, CDCl3) δ 8.35 (d, J = 1.3 Hz, 1H), 7.55 (s, 1H), 7.48 (s, 1H), 6.96 (s, 1H), 6.11 (s, 2H), 5.32–5.29 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 154.2, 151.6, 150.1, 149.4, 148.4, 142.7, 134.1, 128.0, 120.8, 113.4, 106.1, 101.9, 101.7, 61.5. HRMS (ESI): m/z [M+H]+ calcd for C14H8N2O4: 269.0557; found: 269.0556.
Methyl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4d), 38 mg, yellow solid, m.p.: 252–254 °C. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.25 (d, J = 7.7 Hz, 1H), 7.75 (dd, J = 8.4, 1.5 Hz, 1H), 7.67 (ddd, J = 8.5, 6.9, 1.5 Hz, 1H), 7.60 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 5.43 (d, J = 1.3 Hz, 2H), 4.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 165.6, 153.6, 152.4, 145.2, 144.1, 137.0, 130. 6, 129.2, 128.6, 126.1, 124.8, 124.0, 113.4, 62.2, 53.0. HRMS (ESI): m/z [M+H]+ calcd for C15H10N2O4: 283.0713; found: 283.0713.
Ethyl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4e), 44 mg, brown solid. m.p.: 197–198 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.24 (d, J = 7.8 Hz, 1H), 7.75 (dd, J = 8.4, 1.4 Hz, 1H), 7.66 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 7.59 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 5.42 (d, J = 1.3 Hz, 2H), 4.56 (q, J = 7.1 Hz, 2H), 1.46 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 165.2, 153.6, 152.3, 145.1, 144.1, 137.0, 130.5, 129.1, 128.6, 126.1, 125.2, 123.9, 113.4, 62.2, 62.1, 14.3. HRMS (ESI): m/z [M+H]+ calcd for C16H12N2O4: 297.0870; found: 297.0869.
4-Methoxybenzyl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4f), 44 mg, yellow solid, m.p.: 120–122 °C. 1H NMR (500 MHz, CDCl3) δ 8.42 (s, 1H), 8.22 (d, J = 8.4 Hz, 2H), 7.68–7.60 (m, 2H), 7.57–7.50 (m, 1H), 7.43 (d, J = 8.7 Hz, 3H), 6.93 (d, J = 8.7 Hz, 3H), 5.46 (s, 4H), 5.38 (s, 2H), 3.82 (s, 5H). 13C NMR (126 MHz, CDCl3) δ 165.1, 159.9, 153.5, 152.3, 145.2, 144.1, 136.9, 130.5, 130.4, 129.1, 128.5, 127.3, 126.1, 124.8, 123.8, 114.0, 113.4, 67.7, 62.0, 55.3. HRMS (ESI): m/z [M+H]+ calcd for C22H16N2O5:389.1132; found:389.1131.
2-Bromobenzyl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4g), 50 mg, yellow solid, m.p.: 166–168 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.69–7.54 (m, 4H), 7.34 (t, J = 7.5 Hz, 1H), 7.23 (td, J = 7.8, 1.7 Hz, 1H), 5.62 (s, 2H), 5.41 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 164.9, 153.5, 152.4, 145.4, 144.1, 137.0, 134.4, 133.0, 130.5, 130.4, 130.2, 129.2, 128.6, 127.6, 126.1, 124.4, 124.00, 123.7, 113.4, 67.4, 62.1. HRMS (ESI): m/z [M+H]+ calcd for C21H13BrN2O4:437.0131; found:437.0133.
Benzyl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4h), 56 mg, white solid, m.p.: 126–128 °C. 1H NMR (500 MHz, CDCl3) δ 8.43 (d, J = 1.5 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.58–7.52 (m, 1H), 7.49 (d, J = 6.8 Hz, 2H), 7.40 (dt, J = 12.3, 6.8 Hz, 3H), 5.54 (s, 2H), 5.39 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 165.1, 153.5, 152.3, 145.2, 144.1, 137.00, 135.1, 130.5, 129.2, 128.7, 128.6, 128.6, 128.5, 126.1, 124.7, 123.9, 113.4, 67.8, 62.1. HRMS (ESI): m/z [M+H]+ calcd for: C21H14N2O4: 359.1026; found:359.1025.
N,N-Dibenzyl-4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxamide (4i), 45 mg, yellow solid, m.p.: 89–91 °C. 1H NMR (500 MHz, CDCl3) δ 8.46 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 7.74 (d, J = 8.7 Hz, 1H), 7.68 (t, J = 7.6 Hz, 1H), 7.60 (t, J = 7.8 Hz, 1H), 7.52–7.42 (m, 4H), 7.39 (t, J = 6.8 Hz, 1H), 7.32–7.21 (m, 4H), 7.07 (d, J = 6.4 Hz, 2H), 5.48 (d, J = 13.7 Hz, 1H), 5.25 (d, J = 13.6 Hz, 1H), 4.98 (d, J = 14.5 Hz, 1H), 4.79 (d, J = 14.5 Hz, 1H), 4.32–4.21 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 177.2, 166.0, 153.5, 152.4, 144.2, 143.9, 136.7, 136.3, 135.2, 130.5, 129.1, 128.7, 128.7, 128.6, 128.6, 127.8, 127.6, 127.5, 126.4, 123.8, 113.3, 61.9, 51.1, 46.7. HRMS (ESI): m/z [M+H]+ calcd for C28H21N3O3:448.1656; found:448.1656.
4H-Isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinolin-6-yl)(morpholino)methanone (4j), 33 mg, yellow solid, m.p.: over 280 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.22 (d, J = 8.3 Hz, 1H), 7.68 (s, 1H), 7.66 (d, J = 8.9 Hz, 2H), 5.41 (q, J = 13.7 Hz, 2H), 4.03–3.91 (m, 2H), 3.84 (ddt, J = 18.4, 7.8, 5.7 Hz, 2H), 3.62 (ddd, J = 10.1, 6.2, 3.2 Hz, 1H), 3.53 (ddd, J = 11.2, 6.7, 3.2 Hz, 1H), 3.27 (ddd, J = 13.8, 6.7, 3.2 Hz, 1H), 3.19 (ddd, J = 13.6, 6.3, 3.3 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 163.9, 153.6, 152.4, 144.3, 143.9, 136.8, 130.6, 129.2, 128.8, 127.0, 126.2, 123.8, 113.4, 67.0, 66.8, 62.1, 47.0, 42.1. HRMS (ESI): m/z [M+H]+ calcd for C18H15N3O4: 338.1135; found: 338.1132.
(1S,2R,5S)-2-Isopropyl-5-methylcyclohexyl4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4k), 18 mg, yellow solid, m.p.:176–178 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.24 (d, J = 8.5 Hz, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.70–7.64 (m, 1H), 7.64–7.57 (m, 1H), 5.40 (q, J = 13.6 Hz, 2H), 5.13 (td, J = 11.0, 4.3 Hz, 1H), 2.34 (d, J = 12.1 Hz, 1H), 2.11 (pd, J = 6.9, 2.7 Hz, 1H), 1.78–1.72 (m, 2H), 1.63 (d, J = 2.9 Hz, 1H), 1.54–1.46 (m, 1H), 1.28–1.11 (m, 2H), 1.00 (d, J = 6.5 Hz, 3H), 0.92 (dd, J = 7.0, 4.0 Hz, 7H). 13C NMR (126 MHz, CDCl3) δ 165.0, 154.6, 152.3, 144.7, 144.2, 137.0, 130.5, 129.1, 128.6, 126.1, 125.8, 123.8, 113.4, 61.9, 46.9, 40.9, 34.1, 31.6, 26.0, 23.2, 22.0, 20.8, 16.0. HRMS (ESI): m/z [M+H]+ calcd for C24H26N2O4:407.1965; found: 407.1960.
((3aS,4S,6S,6aS)-6-Methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methyl4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4l), 31 mg, yellow solid, m.p.:139–141 °C. 1H NMR (500 MHz, CDCl3) δ 8.45 (s, 1H), 8.25 (d, J = 8.4 Hz, 2H), 7.82 (d, J = 8.3 Hz, 2H), 7.67 (dd, J = 8.4, 7.0 Hz, 2H), 7.64–7.57 (m, 1H), 5.43 (s, 3H), 5.04 (s, 2H), 4.77 (d, J = 5.9 Hz, 2H), 4.66 (d, J = 5.9 Hz, 2H), 4.58–4.52 (m, 3H), 4.51–4.45 (m, 2H), 3.38 (s, 5H), 1.50 (s, 5H), 1.33 (s, 5H). 13C NMR (126 MHz, CDCl3) δ 164.7, 153.5, 152.4, 145.4, 144.1, 137.0, 130.6, 129.3, 128.6, 126.0, 124.4, 123.9, 113.4, 112.7, 109.4, 85.1, 83.9, 81.8, 65.9, 62.1, 55.1, 26.4, 25.0. HRMS (ESI): m/z [M+H]+ calcd for C23H22N2O8:455.1449; found:455.1442.
(7S,11S,E)-3,7,11,15-Tetramethylhexadec-2-en-1-yl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4m), 73 mg, orange oil, 1H NMR (500 MHz, CDCl3) δ 8.44 (d, J = 5.4 Hz, 1H), 8.23 (t, J = 7.3 Hz, 1H), 7.79 (dd, J = 37.8, 8.4 Hz, 1H), 7.65 (q, J = 7.6, 7.0 Hz, 1H), 7.58 (h, J = 8.2, 7.3 Hz, 1H), 5.57–5.48 (m, 1H), 5.41 (s, 2H), 5.00 (t, J = 7.6 Hz, 1H), 4.78–4.68 (m, 1H), 2.25–2.03 (m, 1H), 1.79 (d, J = 8.1 Hz, 2H), 1.51 (dtd, J = 13.2, 6.5, 2.3 Hz, 1H), 1.38–1.18 (m, 4H), 1.15–1.09 (m, 1H), 1.09–1.02 (m, 2H), 0.90–0.76 (m, 12H). 13C NMR (126 MHz, CDCl3) δ 165.2, 153.6, 152.3, 145.0, 144.6, 144.1, 136.9, 130.5, 129.0, 128.5, 126.1, 123.9, 117.9, 117.2, 113.4, 63.0, 62.1, 39.9, 39.3, 37.4, 37.3, 37.2, 36.6, 32.7, 32.6, 27.9, 25.6, 25.1, 24.7, 24.4, 22.7, 22.6, 19.7, 16.5. HRMS (ESI): m/z [M+H]+ calcd for C34H46N2O4:547.3530; found: 547.3528.
(3S,8S,9S,10R,13R,14S,17R)-10,13-Dimethyl-17-((R)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4n), 42 mg, yellow soild, m.p.: 196–197 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.24 (d, J = 8.2 Hz, 1H), 7.81–7.74 (m, 1H), 7.70–7.64 (m, 1H), 7.63–7.58 (m, 1H), 5.49 (d, J = 5.4 Hz, 1H), 5.43 (d, J = 5.1 Hz, 2H), 5.09 (td, J = 11.5, 5.6 Hz, 1H), 2.64–2.46 (m, 2H), 2.18–1.92 (m, 2H), 1.85 (ddd, J = 9.8, 5.8, 3.8 Hz, 1H), 1.62–1.59 (m, 5H), 1.50 (qd, J = 11.4, 9.1, 3.8 Hz, 2H), 1.42–1.33 (m, 2H), 1.25 (ddt, J = 19.4, 13.3, 6.0 Hz, 2H), 1.20–1.07 (m, 3H), 1.05 (s, 4H), 0.93 (d, J = 6.3 Hz, 3H), 0.87 (dd, J = 6.6, 2.3 Hz, 8H), 0.70 (d, J = 8.2 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 164.6, 153.6, 152.3, 144.9, 144.1, 139.2, 137.0, 130.5, 129.1, 128.6, 126.1, 125.5, 123.9, 123.3, 113.5, 76.3, 62.1, 56.7, 56.1, 50.0, 42.3, 39.7, 39.5, 38.1, 37.0, 36.6, 36.2, 35.8, 31.9, 31.8, 28.2, 28.0, 27.9, 24.3, 23.8, 22.8, 22.5, 21.0, 19.3, 18.7, 11.9. HRMS (ESI): m/z [M+H]+ calcd for C41H52N2O4:637.4000; found: 637.4000.
(3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S,E)-5-Ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl 4H-isoxazolo[3′,4′:4,5]pyrano[3,2-b]quinoline-6-carboxylate (4o), 38 mg, yellow solid, m.p.: 213–214 °C. 1H NMR (500 MHz, CDCl3) δ 8.44 (s, 1H), 8.24 (d, J = 8.4 Hz, 1H), 7.77 (dd, J = 8.4, 1.4 Hz, 1H), 7.70–7.63 (m, 1H), 7.63–7.57 (m, 1H), 5.49 (d, J = 5.5 Hz, 1H), 5.43 (s, 2H), 5.27–5.09 (m, 1H), 5.07–4.99 (m, 1H), 2.63–2.46 (m, 2H), 2.18–1.93 (m, 3H), 1.81–1.66 (m, 2H), 1.60–1.45 (m, 3H), 1.29–1.14 (m, 2H), 1.04 (d, J = 13.4 Hz, 5H), 0.93 (d, J = 6.2 Hz, 1H), 0.88–0.78 (m, 7H), 0.70 (d, J = 9.0 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 164.6, 153.6, 152.3, 144.9, 144.1, 139.2, 138.3, 137.0, 130.5, 129.3, 129.1, 128.5, 126.0, 125.5, 123.8, 123.3, 113.4, 76.3, 62.1, 56.8, 55.9, 51.2, 50.0, 45.8, 42.2, 40.5, 39.7, 39.6, 38.1, 37.0, 36.6, 31.9, 31.9, 31.8, 28.9, 27.9, 25.4, 24.3, 21.2, 21.1, 21.0, 19.3, 19.0, 19.0, 12.2, 12.0. HRMS (ESI): m/z [M+H]+ calcd for C43H54N2O4:663.4156; found: 663.4150.
3-Phenyl-2-(5-phenylisoxazol-3-yl)quinazolin-4(3H)-one (6a), 41 mg, yellow soild, m.p.: 120–122 °C. 1H NMR (500 MHz, CDCl3) δ 8.39 (d, J = 8.0 Hz, 1H), 7.92–7.83 (m, 4H), 7.69–7.64 (m, 3H), 7.64–7.58 (m, 1H), 7.52–7.40 (m, 9H), 7.32 (dd, J = 8.0, 1.7 Hz, 3H), 6.51 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 170.1, 161.8, 159.3, 147.1, 145.6, 137.0, 134.9, 130.6, 129.4, 129.0, 128.8, 128.3, 128.2, 127.3, 126.6, 125.9, 121.6. HRMS (ESI): m/z [M+H]+ calcd for C23H15N3O2:366.1237; found: 366.1228.

4. Conclusions

In summary, a facile and practical 1,3-dipolar cycloaddition reaction that accessed a wide variety of isoxazole-fused tricyclic quinazoline alkaloids and their derivatives has been developed under metal-free conditions. In this system, methyl azaarenes were transformed into nitrile oxides in situ by using TBN as the radical initiator and source of N-O without transition metal. This strategy has broad substrate applicability and good functional group tolerance with facile manipulation of readily available starting materials. Natural product modifications confirmed the practical utility of this synthetic method.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28062787/s1, Characterization data for product 2, 4 and 6a, include 1H-NMR, 13C-NMR and high-resolution mass spectrometry (HRMS) spectroscopies are available online.

Author Contributions

Conceptualization, Y.Z. (Yanping Zhu); methodology, Y.Z. (Yanping Zhu); investigation, Z.W. and Y.Z. (Yuhan Zhao); data curation, J.C., M.C., X.L., T.J., F.L., X.Y. and Y.S.; writing—original draft preparation, Z.W., Y.Z. (Yuhan Zhao) and Y.S.; writing—review and editing, Y.Z. (Yanping Zhu); visualization, Z.W.; supervision, Y.Z. (Yanping Zhu); project administration, Y.Z. (Yanping Zhu). All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Science and Technology Innovation Development Plan of Yantai (2020MSGY114), Yantai “Double Hundred Plan” and by the Foundation of Anhui Laboratory of Molecule-Based Materials (fzj22022). The Graduate Innovation Foundation of Yantai University (KGIFYTU2223) is gratefully acknowledged (for Z. Wang).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors also thank the Talent Induction Program for Youth Innovation Teams in Colleges and Universities of Shandong Province.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds 2 and 4 are available from the authors.

References

  1. Fan, Y.L.; Cheng, X.W.; Wu, J.B.; Liu, M.; Zhang, F.Z.; Xu, Z.; Feng, L.S. Antiplasmodial and antimalarial activities of quinolone derivatives: An overview. Eur. J. Med. Chem. 2018, 146, 1–14. [Google Scholar] [CrossRef] [PubMed]
  2. Fan, Y.L.; Wu, J.B.; Cheng, X.W.; Zhang, F.Z.; Feng, L.S. Fluoroquinolone derivatives and their anti-tubercular activities. Eur. J. Med. Chem. 2018, 146, 554–563. [Google Scholar] [CrossRef] [PubMed]
  3. Hu, Y.Q.; Gao, C.; Zhang, S.; Xu, L.; Xu, Z.; Feng, L.S.; Wu, X.; Zhao, F. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 2017, 139, 22–47. [Google Scholar] [CrossRef] [PubMed]
  4. Sekgota, K.C.; Majumder, S.; Isaacs, M.; Mnkandhla, D.; Hoppe, H.C.; Khanye, S.D.; Kriel, F.H.; Coates, J.; Kaye, P.T. Application of the Morita-Baylis-Hillman reaction in the synthesis of 3- (n-cycloalkylbenzamido)methyl -2-quinolones as potential hiv-1 integrase inhibitors. Bioorg. Chem. 2017, 75, 310–316. [Google Scholar] [CrossRef] [PubMed]
  5. Zhang, G.F.; Zhang, S.; Pan, B.F.; Liu, X.F.; Feng, L.S. 4-Quinolone derivatives and their activities against gram positive pathogens. Eur. J. Med. Chem. 2018, 143, 710–723. [Google Scholar] [CrossRef]
  6. Zhang, S.; Xu, Z.; Gao, C.; Ren, Q.C.; Chang, L.; Lv, Z.S.; Feng, L.S. Triazole derivatives and their anti-tubercular activity. Eur. J. Med. Chem. 2017, 138, 501–513. [Google Scholar] [CrossRef]
  7. Chu, X.M.; Wang, C.; Liu, W.; Liang, L.L.; Gong, K.K.; Zhao, C.Y.; Sun, K.L. Quinoline and quinolone dimers and their biological activities: An overview. Eur. J. Med. Chem. 2019, 161, 101–117. [Google Scholar] [CrossRef]
  8. Shang, X.F.; Morris-Natschke, S.L.; Yang, G.Z.; Liu, Y.Q.; Guo, X.; Xu, X.S.; Goto, M.; Li, J.C.; Zhang, J.Y.; Lee, K.H. Biologically active quinoline and quinazoline alkaloids part II. Med. Res. Rev. 2018, 38, 1614–1660. [Google Scholar] [CrossRef]
  9. Swain, S.S.; Pati, S.; Hussain, T. Quinoline heterocyclic containing plant and marine candidates against drug-resistant Mycobacterium tuberculosis: A systematic drug-ability investigation. Eur. J. Med. Chem. 2022, 232, 21. [Google Scholar] [CrossRef]
  10. Yan, Y.M.; Li, X.; Zhang, C.H.; Lv, L.J.; Gao, B.; Li, M.H. Research progress on antibacterial activities and mechanisms of natural alkaloids: A review. Antibiotics 2021, 10, 318. [Google Scholar] [CrossRef]
  11. Auti, P.S.; George, G.; Paul, A.T. Recent advances in the pharmacological diversification of quinazoline/quinazolinone hybrids. RSC Adv. 2020, 10, 41353–41392. [Google Scholar] [CrossRef] [PubMed]
  12. Du, H.T.; Liu, X.L.; Xie, J.S.; Ma, F. Novel deoxyvasicinone-donepezil hybrids as potential multitarget drug candidates for alzheimer’s disease. ACS Chem. Neurosci. 2019, 10, 2397–2407. [Google Scholar] [CrossRef] [PubMed]
  13. Elmuradov, B.Z.; Abdurazakov, A.S.; Shakhidoyatov, K.M. Synthesis and bactericidal activity of 6-h(nitro)-9-arylidenedeoxyvasicinones and their perchlorates. Chem. Nat. Compd. 2008, 44, 475–479. [Google Scholar] [CrossRef]
  14. Khan, I.; Ibrar, A.; Ahmed, W.; Saeed, A. Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: The advances continue. Eur. J. Med. Chem. 2015, 90, 124–169. [Google Scholar] [CrossRef]
  15. Kshirsagar, U.A. Recent developments in the chemistry of quinazolinone alkaloids. Org. Biomol. Chem. 2015, 13, 9336–9352. [Google Scholar] [CrossRef]
  16. Lee, S.E.; Kim, M.J.; Hillman, P.F.; Oh, D.C.; Fenical, W.; Nam, S.J.; Lim, K.M. Deoxyvasicinone with anti-melanogenic activity from marine-derived Streptomyces sp. CNQ-617. Mar. Drugs 2022, 20, 155. [Google Scholar] [CrossRef]
  17. Atta Ur, R.; Sultana, N.; Akhter, F.; Nighat, F.; Choudhary, M.I. Phytochemical studies onadhatoda vasicanees. Nat. Prod. Lett. 1997, 10, 249–256. [Google Scholar] [CrossRef]
  18. Liu, X.; Qian, P.; Wang, Y.; Pan, Y. Metal-free sequential decarbonylative annulation of N-cyanamides for the construction of 2,3-dihydropyrrolo[2,1-b]quinazolin-9(1H)-ones. Org. Chem. Front. 2017, 4, 2370–2374. [Google Scholar] [CrossRef]
  19. Mhaske, S.B.; Argade, N.P. The chemistry of recently isolated naturally occurring quinazolinone alkaloids. Tetrahedron 2006, 62, 9787–9826. [Google Scholar] [CrossRef]
  20. Wang, H.S.; Jiao, S.C.; Chen, K.R.; Zhang, X.; Zhao, L.X.; Liu, D.; Zhou, Y.; Liu, H. Direct access to pyrido/pyrrolo 2,1-b quinazolin-9(1H)-ones through silver-mediated intramolecular alkyne hydroamination reactions. Beilstein J. Org. Chem. 2015, 11, 416–424. [Google Scholar] [CrossRef] [Green Version]
  21. Cagir, A.; Jones, S.H.; Eisenhauer, B.M.; Gao, R.; Hecht, S.M. Synthesis and biochemical properties of E-ring modified luotonin A derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 2051–2054. [Google Scholar] [CrossRef] [PubMed]
  22. Cagir, A.; Jones, S.H.; Gao, R.; Eisenhauer, B.M.; Hecht, S.M.; Luotonin, A. A naturally occurring human dna topoisomerase I poison. J. Am. Chem. Soc. 2003, 125, 13628–13629. [Google Scholar] [CrossRef]
  23. Abdel-Mageed, W.M.; Fayed, M.A.A.; Al-Saleem, M.S.M.; Al-Wahaibi, L.H.; Parvez, M.K.; Li, L.; Al-Dosari, M.S.; Sayed, H.M. Novel polycyclic pyrroloquinazoline alkaloids from Anisotes trisulcus and their biological activity. J. Asian. Nat. Prod. Res. 2020, 22, 1159–1167. [Google Scholar] [CrossRef] [PubMed]
  24. Noh, K.; Seo, Y.M.; Lee, S.K.; Bista, S.R.; Kang, M.J.; Jahng, Y.; Kim, E.; Kang, W.; Jeong, T.C. Effects of rutaecarpine on the metabolism and urinary excretion of caffeine in rats. Arch. Pharm. Res. 2011, 34, 119–125. [Google Scholar] [CrossRef] [PubMed]
  25. Ghosh, P.; Ganguly, B.; Das, S. C-H functionalization of quinazolinones by transition metal catalysis. Org. Biomol. Chem. 2020, 18, 4497–4518. [Google Scholar] [CrossRef]
  26. He, L.; Li, H.Q.; Chen, J.B.; Wu, X.F. Recent advances in 4(3H)-quinazolinone syntheses. RSC Adv. 2014, 4, 12065–12077. [Google Scholar] [CrossRef]
  27. Liu, J.C.; Xiao, X.; Lai, Y.T.; Zhang, Z.M. Recent advances in transition metal-catalyzed heteroannulative difunctionalization of alkenes via C-H activation for the synthesis of heterocycles. Org. Chem. Front. 2022, 9, 2256–2279. [Google Scholar] [CrossRef]
  28. Yang, Y.J.; Zhu, C.J.; Zhang, M.; Huang, S.J.; Lin, J.J.; Pan, X.D.; Su, W.P. Condensation of anthranilic acids with pyridines to furnish pyridoquinazolones via pyridine dearomatization. Chem. Commun. 2016, 52, 12869–12872. [Google Scholar] [CrossRef]
  29. Turner, O.J.; Hirst, D.J.; Murphy, J.A. hydrogen atom transfer-mediated domino cyclisation reaction to access (spiro)quinazolinones. Chem. Eur. J. 2020, 26, 3026–3029. [Google Scholar] [CrossRef]
  30. Turner, O.J.; Murphy, J.A.; Hirst, D.J.; Talbot, E.P.A. Hydrogen atom transfer-mediated cyclisations of nitriles. Chem. Eur. J. 2018, 24, 18658–18662. [Google Scholar] [CrossRef] [Green Version]
  31. Xu, G.; Tong, C.D.; Cui, S.L.; Dai, L.Y. A silver catalyzed domino reaction of N-cyanamide alkenes and 1,3-dicarbonyls for the synthesis of quinazolinones. Org. Biomol. Chem. 2018, 16, 5899–5906. [Google Scholar] [CrossRef]
  32. Liu, H.; Yang, Z.X.; Huang, G.; Yu, J.T.; Pan, C.D. Cyanomethylative cyclization of unactivated alkenes with nitriles for the synthesis of cyano-containing ring-fused quinazolin-4(3H)-ones. New J. Chem. 2022, 46, 1347–1352. [Google Scholar] [CrossRef]
  33. Sun, B.; Huang, P.Y.; Yan, Z.Y.; Shi, X.Y.; Tang, X.L.; Yang, J.; Jin, C. Self-catalyzed phototandem perfluoroalkylation/cyclization of unactivated alkenes: Synthesis of perfluoroalkyl-substituted quinazolinones. Org. Lett. 2021, 23, 1026–1031. [Google Scholar] [CrossRef] [PubMed]
  34. Sun, B.; Shi, R.; Zhang, K.; Tang, X.; Shi, X.; Xu, J.; Yang, J.; Jin, C. Photoinduced homolytic decarboxylative acylation/cyclization of unactivated alkenes with α-keto acid under external oxidant and photocatalyst free conditions: Access to quinazolinone derivatives. Chem. Commun. 2021, 57, 6050–6053. [Google Scholar] [CrossRef]
  35. Yang, J.; Sun, B.; Ding, H.; Huang, P.Y.; Tang, X.L.; Shi, R.C.; Yan, Z.Y.; Yu, C.M.; Jin, C. Photo-triggered self-catalyzed fluoroalkylation/cyclization of unactivated alkenes: Synthesis of quinazolinones containing the CF2R group. Green Chem. 2021, 23, 575–581. [Google Scholar] [CrossRef]
  36. Chen, X.; Xia, F.; Zhao, Y.; Ma, J.; Ma, Y.; Zhang, D.; Yang, L.; Sun, P. TBHP-mediated oxidative decarboxylative cyclization in water: Direct and sustainable access to anti-malarial polycyclic fused quinazolinones and rutaecarpine. Chin. J. Chem. 2020, 38, 1239–1244. [Google Scholar] [CrossRef]
  37. Chen, X.; Zhang, X.; Lu, S.; Sun, P. Electrosynthesis of polycyclic quinazolinones and rutaecarpine from isatoic anhydrides and cyclic amines. RSC Adv. 2020, 10, 44382–44386. [Google Scholar] [CrossRef]
  38. Jing, D.; Lu, C.; Chen, Z.; Jin, S.Y.; Xie, L.J.; Meng, Z.Y.; Su, Z.S.; Zheng, K. Light-driven intramolecular c-n cross-coupling via a long-lived photoactive photoisomer complex. Angew. Chem. Int. Edit. 2019, 58, 14666–14672. [Google Scholar] [CrossRef] [PubMed]
  39. Lu, C.; Su, Z.S.; Jing, D.; Jin, S.Y.; Xie, L.J.; Li, L.R.; Zheng, K. Intramolecular reductive cyclization of o-nitroarenes via biradical recombination. Org. Lett. 2019, 21, 1438–1443. [Google Scholar] [CrossRef]
  40. Xie, F.; Chen, Q.H.; Xie, R.; Jiang, H.F.; Zhang, M. MOF-derived nanocobalt for oxidative functionalization of cyclic amines to quinazolinones with 2-aminoarylmethanols. ACS Catal. 2018, 8, 5869–5874. [Google Scholar] [CrossRef]
  41. Xie, L.; Lu, C.; Jing, D.; Ou, X.; Zheng, K. Metal-free synthesis of polycyclic quinazolinones enabled by a (nh4)2s2o8-promoted intramolecular oxidative cyclization. Eur. J. Org. Chem. 2019, 2019, 3649–3653. [Google Scholar] [CrossRef]
  42. Dabiri, M.; Lehi, N.F.; Movahed, S.K.; Khavasi, H.R. Palladium catalyzed cross-dehydrogenative coupling/annulation reaction: A practical and efficient approach to hydroxyisoindolo[1,2-b]quinazolinone. Eur. J. Org. Chem. 2019, 2019, 2933–2940. [Google Scholar] [CrossRef]
  43. Wang, W.; Zou, P.-S.; Pang, L.; Lei, Y.; Huang, Z.-Y.; Chen, N.-Y.; Mo, D.-L.; Pan, C.-X.; Su, G.-F. Synthesis of spiroindolenine-3,3′-pyrrolo[2,1-b]quinazolinones through gold(i)-catalyzed dearomative cyclization of N-alkynyl quinazolinone-tethered indoles. Org. Biomol. Chem. 2022, 20, 2069–2074. [Google Scholar] [CrossRef]
  44. Ali, I.; Lone, N.M.; Al-Othman, A.Z.; Al-Warthan, A.; Sanagi, M.M. Heterocyclic scaffolds: Centrality in anticancer drug development. Curr. Cancer Drug Tar. 2015, 16, 711–734. [Google Scholar] [CrossRef] [PubMed]
  45. Martorana, A.; Giacalone, V.; Bonsignore, R.; Pace, A.; Gentile, C.; Pibiri, I.; Buscemi, S.; Lauria, A.; Piccionello, P.A. Heterocyclic scaffolds for the treatment of Alzheimer’s Disease. Curr. Pharm. Design 2016, 22, 3971–3995. [Google Scholar] [CrossRef] [PubMed]
  46. Zhu, J.; Mo, J.; Lin, H.-z.; Chen, Y.; Sun, H.-p. The recent progress of isoxazole in medicinal chemistry. Bioorg. Med. Chem. 2018, 26, 3065–3075. [Google Scholar] [CrossRef]
  47. Barmade, A.M.; Murumkar, R.P.; Sharma, K.M.; Yadav, R.M. Medicinal chemistry perspective of fused isoxazole derivatives. Curr. Top. Med. Chem. 2016, 16, 2863–2883. [Google Scholar] [CrossRef] [PubMed]
  48. Neha, K.; Wakode, S. Contemporary advances of cyclic molecules proposed for inflammation. Eur. J. Med. Chem. 2021, 221, 113493. [Google Scholar] [CrossRef] [PubMed]
  49. Sysak, A.; Obmińska-Mrukowicz, B. Isoxazole ring as a useful scaffold in a search for new therapeutic agents. Eur. J. Med. Chem. 2017, 137, 292–309. [Google Scholar] [CrossRef]
  50. Chen, F.; Huang, X.; Li, X.; Shen, T.; Zou, M.; Jiao, N. Dehydrogenative n-incorporation: A direct approach to quinoxaline n-oxides under mild conditions. Angew. Chem. Int. Edit. 2014, 53, 10495–10499. [Google Scholar] [CrossRef]
  51. Pan, J.; Li, X.; Lin, F.; Liu, J.; Jiao, N. Chemoselective nitrosylation of anilines and alkynes via fragmentary or complete no incorporation. Chemistry 2018, 4, 1427–1442. [Google Scholar] [CrossRef] [Green Version]
  52. Chaudhary, P.; Gupta, S.; Muniyappan, N.; Sabiah, S.; Kandasamy, J. An efficient synthesis of N-nitrosamines under solvent, metal and acid free conditions using tert-butyl nitrite. Green Chem. 2016, 18, 2323–2330. [Google Scholar] [CrossRef]
  53. Ma, X.; Song, Q. Tert-Butyl nitrite mediated synthesis of fluorinated o-alkyloxime ether derivatives. Org. Lett. 2019, 21, 7375–7379. [Google Scholar] [CrossRef]
  54. Mir, B.A.; Singh, S.J.; Kumar, R.; Patel, B.K. tert-Butyl nitrite mediated different functionalizations of internal alkenes: Paths to furoxans and nitroalkenes. Adv. Synth. Catal. 2018, 360, 3801–3809. [Google Scholar] [CrossRef]
  55. Sau, P.; Rakshit, A.; Modi, A.; Behera, A.; Patel, B.K. Three sequential c-n bond formations: Tert-butyl nitrite as a N1 synthon in a three component reaction leading to imidazo 1,2-a quinolines and imidazo 2,1-a isoquinolines. J. Org. Chem. 2018, 83, 1056–1064. [Google Scholar] [CrossRef]
  56. Shu, Z.B.; Ye, Y.X.; Deng, Y.F.; Zhang, Y.; Wang, J.B. Palladium(II)-catalyzed direct conversion of methyl arenes into aromatic nitriles. Angew. Chem. Int. Edit. 2013, 52, 10573–10576. [Google Scholar] [CrossRef]
  57. Wan, L.; Qiao, K.; Yuan, X.; Zheng, M.W.; Fan, B.B.; Di, Z.C.; Zhang, D.; Fang, Z.; Guo, K. Nickel-catalyzed regioselective C-H Bond mono- and bis-nitration of aryloxazolines with tert-butyl nitrite as nitro source. Adv. Synth. Catal. 2017, 359, 2596–2604. [Google Scholar] [CrossRef]
  58. Yang, X.-H.; Song, R.-J.; Li, J.-H. Metal-free [4+2] annulation of arylalkynes with tert-butyl nitrite through C(sp2)-H oxidation to assemble benzo[e][1,2]oxazin-4-ones. Adv. Synth. Catal. 2015, 357, 3849–3856. [Google Scholar] [CrossRef]
  59. Dahiya, A.; Sahoo, A.K.; Alam, T.; Patel, B.K. tert-Butyl Nitrite (TBN), a multitasking reagent in organic synthesis. Chem. Asian J. 2019, 14, 4454–4492. [Google Scholar] [CrossRef]
  60. Gao, P.; Li, H.X.; Hao, X.H.; Jin, D.P.; Chen, D.Q.; Yan, X.B.; Wu, X.X.; Song, X.R.; Liu, X.Y.; Liang, Y.M. Facile synthesis of disubstituted isoxazoles from homopropargylic alcohol via C=N bond formation. Org. Lett. 2014, 16, 6298–6301. [Google Scholar] [CrossRef]
  61. Sau, P.; Santra, S.K.; Rakshit, A.; Patel, B.K. tert-Butyl nitrite-mediated domino synthesis of isoxazolines and isoxazoles from terminal aryl alkenes and alkynes. J. Org. Chem. 2017, 82, 6358–6365. [Google Scholar] [CrossRef] [PubMed]
  62. Chen, R.X.; Zhao, Y.W.; Fang, S.W.; Long, W.H.; Sun, H.M.; Wan, X.B. Coupling reaction of cu-based carbene and nitroso radical: A tandem reaction to construct isoxazolines. Org. Lett. 2017, 19, 5896–5899. [Google Scholar] [CrossRef] [PubMed]
  63. Chen, R.X.; Ogunlana, A.A.; Fang, S.W.; Long, W.H.; Sun, H.M.; Bao, X.G.; Wan, X.B. In situ generation of nitrile oxides from copper carbene and tert-butyl nitrite: Synthesis of fully substituted isoxazoles. Org. Biomol. Chem. 2018, 16, 4683–4687. [Google Scholar] [CrossRef] [PubMed]
  64. Zhang, X.W.; Hu, W.L.; Chen, S.; Hu, X.G. Cu-catalyzed synthesis of fluoroalkylated isoxazoles from commercially available amines and alkynes. Org. Lett. 2018, 20, 860–863. [Google Scholar] [CrossRef] [PubMed]
  65. Wang, X.-D.; Zhu, L.-H.; Liu, P.; Wang, X.-Y.; Yuan, H.-Y.; Zhao, Y.-L. Copper-catalyzed cascade cyclization reactions of diazo compounds with tert-butyl nitrite and alkynes: One-pot synthesis of isoxazoles. J. Org. Chem. 2019, 84, 16214–16221. [Google Scholar] [CrossRef]
  66. Zhang, X.-W.; He, X.-L.; Yan, N.; Zheng, H.-X.; Hu, X.-G. Oxidize Amines to nitrile oxides: One type of amine oxidation and its application to directly construct isoxazoles and isoxazolines. J. Org. Chem. 2020, 85, 15726–15735. [Google Scholar] [CrossRef]
  67. Yue, X.; Hu, M.; He, X.; Wu, S.; Li, J.-H. A radical-mediated 1,3,4-trifunctionalization cascade of 1,3-enynes with sulfinates and tert-butyl nitrite: Facile access to sulfonyl isoxazoles. Chem. Commun. 2020, 56, 6253–6256. [Google Scholar] [CrossRef]
  68. Ma, L.; Jin, F.; Cheng, X.; Tao, S.Y.; Jiang, G.Z.; Li, X.X.; Yang, J.W.; Bao, X.G.; Wan, X.B. 2+2+1 Cycloaddition of N-tosylhydrazones, tert-butyl nitrite and alkenes: A general and practical access to isoxazolines. Chem. Sci. 2021, 12, 9823–9830. [Google Scholar] [CrossRef]
  69. Ma, L.; Kou, L.Y.; Jin, F.; Cheng, X.L.; Tao, S.Y.; Jiang, G.Z.; Bao, X.G.; Wan, X.B. Acyclic nitronate olefin cycloaddition (ANOC): Regio- and stereospecific synthesis of isoxazolines. Chem. Sci. 2021, 12, 774–779. [Google Scholar] [CrossRef]
  70. Dai, P.; Tan, X.; Luo, Q.; Yu, X.; Zhang, S.; Liu, F.; Zhang, W.-H. Synthesis of 3-acyl-isoxazoles and Δ2-isoxazolines from methyl ketones, alkynes or alkenes, and tert-butyl nitrite via a Csp3-H radical functionalization/cycloaddition cascade. Org. Lett. 2019, 21, 5096–5100. [Google Scholar] [CrossRef]
  71. Wang, G.-W.; Cheng, M.-X.; Ma, R.-S.; Yang, S.-D. Cu-catalyzed selective cascade sp3 C–H bond oxidative functionalization towards isoxazoline derivatives. Chem. Commun. 2015, 51, 6308–6311. [Google Scholar] [CrossRef] [PubMed]
  72. Wang, G.-W.; Li, S.-X.; Wu, Q.-X.; Yang, S.-D. Cu-catalyzed sp3 C–H bond oxidative functionalization of alkylazaarenes and substituted ethanones: An efficient approach to isoxazoline derivatives. Org. Chem. Front. 2015, 2, 569–573. [Google Scholar] [CrossRef]
  73. Tang, Z.; Zhou, Y.; Song, Q. Synthesis of furoxans and isoxazoles via divergent [2 + 1 + 1 + 1] annulations of sulfoxonium ylides and t-buONO. Org. Lett. 2019, 21, 5273–5276. [Google Scholar] [CrossRef] [PubMed]
  74. Zhang, X.-J.; Cao, J.-K.; Ren, J.-J.; Hong, L.; Liang, R.-J.; Hao, K.-Y.; Wei, K.-L.; Mi, B.-J.; Liu, Y.; Zhu, Y.-P. Generation of azaarene nitrile oxides from methyl azaarenes and t-BuONO enabling the synthesis of furoxans and 1,2,4-oxadiazoles. Org. Chem. Front. 2022, 9, 1121–1126. [Google Scholar] [CrossRef]
  75. Jiang, C.; Chen, Y.; Gao, P.; Zhang, S.; Jia, X.; Yuan, Y. Direct transformation of nitrogen-containing methylheteroarenes to heteroaryl nitrile by sodium nitrite. Org. Lett. 2022, 24, 6341–6345. [Google Scholar] [CrossRef]
  76. Wang, D.; Zhang, F.; Xiao, F.; Deng, G.-J. A three-component approach to isoxazolines and isoxazoles under metal-free conditions. Org. Biomol. Chem. 2019, 17, 9163–9168. [Google Scholar] [CrossRef]
  77. Yu, J.; Lu, M. Copper(ii)-promoted direct conversion of methylarenes into aromatic oximes. Org. Biomol. Chem. 2015, 13, 7397–7401. [Google Scholar] [CrossRef]
  78. Jones, M.L. Heterocyclic Compounds as Antibiotic Potentiators. U.S. Patent Application No 14/965,759, 12 December 2014. [Google Scholar]
  79. Ouahrouch, A.; Taourirte, M.; Engels, J.W.; Benjelloun, S.; Lazrek, H.B. Synthesis of new 1,2,3-triazol-4-yl-quinazoline nucleoside and acyclonucleoside analogues. Molecules 2014, 19, 3638–3653. [Google Scholar] [CrossRef] [Green Version]
  80. Liu, X.; Fu, H.; Jiang, Y.; Zhao, Y. A Simple and efficient approach to quinazolinones under mild copper-catalyzed conditions. Angew. Chem. Int. Edit. 2009, 48, 348–351. [Google Scholar] [CrossRef]
  81. An, S.-Z. Compound as WNT Signaling Inhibitor, Composition, and Use Thereof. U.S. Patent No 9,556,144, 29 January 2015. [Google Scholar]
  82. Mamedov, V.A.; Mamedova, V.L.; Syakaev, V.V.; Korshin, D.E.; Khikmatova, G.n.Z.; Mironova, E.V.; Bazanova, O.B.; Rizvanov, I.d.K.; Latypov, S.K. Simple synthesis of 3-hydroxyquinolines via Na2S2O4-mediated reductive cyclization of (2-(2-nitrophenyl)oxiran-1-yl)(aryl)methanones(o-nitrobenzalacetophenone oxides). Tetrahedron 2017, 73, 5082–5090. [Google Scholar] [CrossRef]
  83. Choi, J.-K. Protein tyrosine phosphatase 1b inhibitors: Heterocyclic carboxylic acids. ChemInform 2004, 35, 1455–1464. [Google Scholar] [CrossRef]
  84. Zhang, W.; Li, Z.; Zhou, M.; Wu, F.; Hou, X.; Luo, H.; Liu, H.; Han, X.; Yan, G.; Ding, Z.; et al. Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. Bioorg. Med. Chem. Lett. 2014, 24, 799–807. [Google Scholar] [CrossRef]
  85. Aspée, A.; García, O.; Maretti, L.; Sastre, R.; Scaiano, J.C. Free radical reactions in poly(methyl methacrylate) films monitored using a prefluorescent quinoline−TEMPO sensor. Macromolecules 2003, 36, 3550–3556. [Google Scholar] [CrossRef]
  86. Kumar, D.; Jadhavar, P.S.; Nautiyal, M.; Sharma, H.; Meena, P.K.; Adane, L.; Pancholia, S.; Chakraborti, A.K. Convenient synthesis of 2,3-disubstituted quinazolin-4(3H)-ones and 2-styryl-3-substituted quinazolin-4(3H)-ones: Applications towards the synthesis of drugs. RSC Adv. 2015, 5, 30819–30825. [Google Scholar] [CrossRef]
  87. Farghaly, A.M.; Mohsen, A.; Omar, M.E.; Khalil, M.A.; Gaber, M.A. Synthesis of 3-aryl-2-substituted-4(3H)-quinazolines as potential antimicrobial agents. Farmaco 1990, 454, 431–438. [Google Scholar]
  88. Rai, B.K.; Thakur, R.K.; Kumari, M. Synthesis and characterisation of Co(II) complexes with some new quinazolone oximes. Asian J. Chem. 2001, 13, 651–655. [Google Scholar]
Molecules 28 02787 g001 550
Figure 1. Representative molecules containing tricyclic quinazoline.
Figure 1. Representative molecules containing tricyclic quinazoline.
Molecules 28 02787 g001
Molecules 28 02787 sch001 550
Scheme 1. Strategies for the synthesis of 2,3-fused quinazolin-4(3H)-ones. (a) Current methods to synthesize tricyclic quinazoline alkaloid. (b) Our previous work forming 1,3-dipolar nitrile oxide from methyl azaarenes via TBN. (c) Our current work to form 1,3-dipolar nitrile oxide from propargyl-substituted methyl azaarenes via TBN.
Scheme 1. Strategies for the synthesis of 2,3-fused quinazolin-4(3H)-ones. (a) Current methods to synthesize tricyclic quinazoline alkaloid. (b) Our previous work forming 1,3-dipolar nitrile oxide from methyl azaarenes via TBN. (c) Our current work to form 1,3-dipolar nitrile oxide from propargyl-substituted methyl azaarenes via TBN.
Molecules 28 02787 sch001
Molecules 28 02787 g002 550
Figure 2. Scope of 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one a,b. a Reaction conditions: 1 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields. c Not detected.
Figure 2. Scope of 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one a,b. a Reaction conditions: 1 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields. c Not detected.
Molecules 28 02787 g002
Molecules 28 02787 g003 550
Figure 3. Scope of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline a,b. a Reaction conditions: 3 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields.
Figure 3. Scope of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline a,b. a Reaction conditions: 3 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields.
Molecules 28 02787 g003
Molecules 28 02787 g004 550
Figure 4. Modification of natural products a,b. a Reaction conditions: 3 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields.
Figure 4. Modification of natural products a,b. a Reaction conditions: 3 (0.2 mmol), TBN (1.1 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under Ar. b Isolated yields.
Molecules 28 02787 g004
Molecules 28 02787 sch002 550
Scheme 2. Control experiments. (a) Radical capture. (b) Formation of intermediate 5ac. (c) Formation of isoxazole 6a via intermolecular cycloaddition under standard conditions. (d) Formation of 6a from intermediate 5ab under standard conditions.
Scheme 2. Control experiments. (a) Radical capture. (b) Formation of intermediate 5ac. (c) Formation of isoxazole 6a via intermolecular cycloaddition under standard conditions. (d) Formation of 6a from intermediate 5ab under standard conditions.
Molecules 28 02787 sch002
Molecules 28 02787 sch003 550
Scheme 3. Proposed mechanism.
Scheme 3. Proposed mechanism.
Molecules 28 02787 sch003
Molecules 28 02787 sch004 550
Scheme 4. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one 1a–1l.
Scheme 4. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one 1a–1l.
Molecules 28 02787 sch004
Molecules 28 02787 sch005 550
Scheme 5. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 1m.
Scheme 5. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yl)pyrido[2,3-d]pyrimidin-4(3H)-one 1m.
Molecules 28 02787 sch005
Molecules 28 02787 sch006 550
Scheme 6. General procedure for synthesis of 2-methyl-7-phenyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one 1g–1h.
Scheme 6. General procedure for synthesis of 2-methyl-7-phenyl-3-(prop-2-yn-1-yl)quinazolin-4(3H)-one 1g–1h.
Molecules 28 02787 sch006
Molecules 28 02787 sch007 550
Scheme 7. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline 4a–4c.
Scheme 7. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline 4a–4c.
Molecules 28 02787 sch007
Molecules 28 02787 sch008 550
Scheme 8. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline-4-carboxylate 3d–3o.
Scheme 8. General procedure for synthesis of 2-methyl-3-(prop-2-yn-1-yloxy)quinoline-4-carboxylate 3d–3o.
Molecules 28 02787 sch008
Molecules 28 02787 sch009 550
Scheme 9. Procedure for synthesis of (E)-4-oxo-3-phenyl-3,4-dihydroquinazoline-2-carbaldehyde oxime (5ab).
Scheme 9. Procedure for synthesis of (E)-4-oxo-3-phenyl-3,4-dihydroquinazoline-2-carbaldehyde oxime (5ab).
Molecules 28 02787 sch009
Table
Table 1. Optimization of reaction conditions a.
Table 1. Optimization of reaction conditions a.
Molecules 28 02787 i001
EntrySolventAcidAdditiveTemp
(°C)		Yield b
(%)
1DMSO 8045
2DMF 8062
31,4-Dioxane 8056
4MeCN 8064
5MeCN 6055
6MeCN 10065
7 cMeCN 10072
8 c,dMeCN 10075
9 c,dMeCN NCS10076
10 c,dMeCNTFANCS10046
11 c,dMeCNAcOHNCS10080
12 c,dMeCNPropanoic acidNCS10068
13 c,dMeCNPropanedioic acidNCS10058
14 c,dMeCN4-Nitrobenzoic acidNCS10068
15 c,dMeCN2-Nitrobenzoic acidNCS10073
16 c,dMeCN4-Chlorobenzoic acidNCS10071
17 c,dMeCNPTA eNCS10055
18 c,dMeCNAcOH 10066
19 c,dMeCN4-Chlorobenzoic acid 10042
a Reaction conditions: 1a (0.2 mmol), TBN (1.0 mmol), NCS (0.1 mmol), AcOH (0.1 mmol) were stirred in acetonitrile (2 mL) at 100 °C for 6 h under air. b Isolated yields. c TBN (5.5 equiv.). d under argon. e p-Toluic acid.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wang, Z.; Zhao, Y.; Chen, J.; Chen, M.; Li, X.; Jiang, T.; Liu, F.; Yang, X.; Sun, Y.; Zhu, Y. One-Pot Synthesis of Isoxazole-Fused Tricyclic Quinazoline Alkaloid Derivatives via Intramolecular Cycloaddition of Propargyl-Substituted Methyl Azaarenes under Metal-Free Conditions. Molecules 2023, 28, 2787. https://doi.org/10.3390/molecules28062787

AMA Style

Wang Z, Zhao Y, Chen J, Chen M, Li X, Jiang T, Liu F, Yang X, Sun Y, Zhu Y. One-Pot Synthesis of Isoxazole-Fused Tricyclic Quinazoline Alkaloid Derivatives via Intramolecular Cycloaddition of Propargyl-Substituted Methyl Azaarenes under Metal-Free Conditions. Molecules. 2023; 28(6):2787. https://doi.org/10.3390/molecules28062787

Chicago/Turabian Style

Wang, Zhuo, Yuhan Zhao, Jiaxin Chen, Mengyao Chen, Xuehan Li, Ting Jiang, Fang Liu, Xi Yang, Yuanyuan Sun, and Yanping Zhu. 2023. "One-Pot Synthesis of Isoxazole-Fused Tricyclic Quinazoline Alkaloid Derivatives via Intramolecular Cycloaddition of Propargyl-Substituted Methyl Azaarenes under Metal-Free Conditions" Molecules 28, no. 6: 2787. https://doi.org/10.3390/molecules28062787

APA Style

Wang, Z., Zhao, Y., Chen, J., Chen, M., Li, X., Jiang, T., Liu, F., Yang, X., Sun, Y., & Zhu, Y. (2023). One-Pot Synthesis of Isoxazole-Fused Tricyclic Quinazoline Alkaloid Derivatives via Intramolecular Cycloaddition of Propargyl-Substituted Methyl Azaarenes under Metal-Free Conditions. Molecules, 28(6), 2787. https://doi.org/10.3390/molecules28062787

Article Metrics

Back to TopTop